Can FDA 510(k) replace EU MDR Class III review?

No. FDA clearance does not substitute for EU MDR conformity assessment.

What GHMAP package helps with EU planning?

Regulatory Pathway Brief ($1,800) or Full Country Intelligence ($5,000) for a product-specific decision after scope lock.

Start Project

GHMAP

Class III pathway in European Union

EU MDR market-access overview for class iii devices. Planning intelligence only — not a regulatory determination, approval, or clinical decision support.

Source trackedEurope

Timelines, fees, and workflow steps on this page are illustrative market-access planning inputs. They are not legal advice, regulatory approval, or a guarantee of registration, reimbursement, or market entry. Professional review with primary-source verification is required before business use.

Regulatory metrics

Planning ranges for this country and device class. Label every figure as illustrative until sources are verified.

Regulatory pathway metrics for Class III in European Union
Metric	Value	Status
Authority	EU MDR Notified Body / Competent Authorities	Source tracked
Device class	Class III	Example only
Average timeline	~420 days / ~14 months (illustrative)	To be verified
Local representative required	Yes — European Authorized Representative (if non-EU manufacturer)	To be verified
Government / assessment fee	~$45,000 USD (illustrative)	Source required

Submission workflow

Step-by-step planning outline. Owners and sequence vary by product evidence and authority questions.

01
Confirm Class III and clinical strategy
Classification, clinical evaluation plan, and PMCF strategy.
Owner: Manufacturer
02
Complete technical documentation
Full MDR technical file including risk management and GSPR evidence.
Owner: Manufacturer
03
Notified Body conformity assessment
Design dossier / clinical evaluation review by the NB.
Owner: Manufacturer / NB
04
Close findings and obtain CE certificate
Resolve NB nonconformities; receive CE certificate.
Owner: Manufacturer
05
Post-market and EUDAMED obligations
Vigilance, SSCP where applicable, and UDI registration.
Owner: Manufacturer / AR

Frequently asked questions

Can FDA 510(k) replace EU MDR Class III review?: No. FDA clearance does not substitute for EU MDR conformity assessment.
What GHMAP package helps with EU planning?: Regulatory Pathway Brief ($1,800) or Full Country Intelligence ($5,000) for a product-specific decision after scope lock.

Related market-access pages

Cross-links between pathway pages, country intelligence, and certification primers.

Other European Union classes

Country intelligence

Broader market, reimbursement, and procurement context for European Union.

Open country profile

Related certifications

Convert planning into a scoped GHMAP engagement

Public pathway pages are general context. Product-specific decisions use request-first market entry packages with written scope lock before research begins.

$5,000 · 15 business days after complete intake and scope lock

Full Country Intelligence

Product-specific market-entry decision for one healthcare or MedTech product in one target country. Includes the Decision Report, Evidence & Calculations Workbook, a 60-minute analyst debrief, and one consolidated revision round.

Request Country Intelligence

$7,500 · 20 business days after complete intake and scope lock

Distributor Search & Qualification

Evidence-based distributor search for one defined MedTech or IVD product in one selected country: 10–15 screened candidates, 10 detailed assessments, and 3–5 recommended for outreach when evidence supports it.

Request Distributor Search

Prefer a shorter briefing first? Request a Regulatory Pathway Brief ($1,800).

Market entry packages

Ready to scope European Union?

GHMAP confirms written scope before Country Intelligence or Distributor Search research begins. Payment never auto-approves introductions or workspace access.

Start Country Intelligence Read disclaimer

Professional review remains part of every GHMAP deliverable.